European companies try to maintain dominance of global contrastmarketPrice erosion and generic competition top list of concernsProvided they steer a steady course, Schering, Nycomed, and Bracco-- the three European companies that dominate
Provided they steer a steady course, Schering, Nycomed, and Bracco-- the three European companies that dominate the contrast mediaindustry -- can look forward to slow but steady growth throughthe end of the century. Rising volumes in x-ray contrast agentusage should just about make up for lower prices. The ultrasoundand MRI sectors, yet to take off in the way some industry observershad predicted, should start to pick up as new agents move fromthe R&D laboratory to the market.
But there are pitfalls ahead. Debstabilization awaits the x-raymarket, due to excessive discounting of products that are notnotably different from their competitors, and the threat of competitionfrom generic nonionic agents is on the horizon. In addition, consolidationcould again change the rules of the market if one or more of themain diagnostic imaging players falls victim to the wave of restructuringsweeping over the wider pharmaceutical industry.
Marketline International, a London-based market research company,put the value of the global contrast media market in 1995 at $3.4billion, up 6.5% from the previous year. Since 1993, Japan hasovertaken the U.S. as the largest individual market, worth $1.5billion, or 42.3% of the total.
The value of the European market for nonionic x-ray contrast mediais $600 million, while the value of the MRI contrast market inEurope is $70 million to $80 million, according to Hafslund Nycomedof Oslo, Norway.
The European market is dominated by Nycomed, Schering of Berlin,and Milan-based Bracco, the family-run company in which anotherGerman firm, E. Merck, has a 50% stake. Guerbet of France andMallinckrodt Medical of the U.S. are the final members of theprevailing oligopoly. Schering and Nycomed also dominate the worldmarket. Schering's own figures give it 31% of the world market,and Nycomed 18%, in 1994. Daiichi's 14% share is entirely dueto Japanese sales of the Nycomed product Omnipaque.
Key Chest CT Parameters for Body Composition May be Prognostic for Patients with Resectable NSCLC
February 11th 2025A high intermuscular adipose index has a 49 percent increased likelihood of being associated with lower overall survival in patients with resectable non-small cell lung cancer (NSCLC), according to new research.
Comparative AI Study Shows Merits of RapidAI LVO Software in Stroke Detection
February 6th 2025The Rapid LVO AI software detected 33 percent more cases of large vessel occlusion (LVO) on computed tomography angiography (CTA) than Viz LVO AI software, according to a new comparative study presented at the International Stroke Conference (ISC).